Arrowstreet Capital, Limited Partnership Alnylam Pharmaceuticals, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$143.31 - $247.0 $2.15 Million - $3.7 Million	14,971 New	14,971 $3.64 Million
Q1 2021 May 14, 2021	SELL	$126.83 - $175.69 $7.77 Million - $10.8 Million	-61,300 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $7.08 Million - $8.46 Million	57,583 Added 1549.18%	61,300 $7.97 Million
Q3 2020 Nov 12, 2020	BUY	$121.19 - $165.49 $183,845 - $251,048	1,517 Added 68.95%	3,717 $541,000
Q2 2020 Aug 12, 2020	BUY	$104.21 - $156.44 $229,262 - $344,168	2,200 New	2,200 $326,000
Q1 2020 May 15, 2020	SELL	$93.12 - $133.99 $307,296 - $442,167	-3,300 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$74.51 - $124.23 $245,883 - $409,959	3,300 New	3,300 $380,000
Q4 2017 Feb 09, 2018	SELL	$114.49 - $139.98 $5.89 Million - $7.21 Million	-51,485 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$72.53 - $118.27 $3.73 Million - $6.09 Million	51,485	51,485 $6.05 Million

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.